JO3502B1 - البولي بيبتيدات المشتقة من عامل نمو التحويل بيتا واستخداماتها - Google Patents

البولي بيبتيدات المشتقة من عامل نمو التحويل بيتا واستخداماتها

Info

Publication number
JO3502B1
JO3502B1 JOP/2013/0317A JOP20130317A JO3502B1 JO 3502 B1 JO3502 B1 JO 3502B1 JO P20130317 A JOP20130317 A JO P20130317A JO 3502 B1 JO3502 B1 JO 3502B1
Authority
JO
Jordan
Prior art keywords
tgfβ
diseases
alk5
interact
ability
Prior art date
Application number
JOP/2013/0317A
Other languages
English (en)
Inventor
Monzon Kalet Leon
Rodriguez Saumel Perez
Merino Amaury Pupo
Osorio Jesus Corria
Portilla Tania Carmenate
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49765213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3502(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Application granted granted Critical
Publication of JO3502B1 publication Critical patent/JO3502B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

يرتبط الاختراع الحالي بمجال التقنية الحيوية و بالأخص أكثر بالببتيدات المتعددة المتحولة من جزيء <span dir="LTR">TGFβ</span> الذي تتصف سلسلته الأساسية بتماثل عالي مع سلسلة <span dir="LTR">TGFβ</span> البشرية تفقد هذه الميوتينات قدرتها على التفاعل مع <span dir="LTR">ALK5</span> و لكنها تحافظ على قدرتها في التفاعل مع المستقبلات الأخرى التي تشكل جزءا من صيغة المستقبل <span dir="LTR">TβRII and TβRIII)</span>). كما و تتمتع بخاصية منع إرسال الإشارات لكافة المتغيرات الطبيعية من روابط <span dir="LTR">TGFβ</span> المعتمدة على تحفيز <span dir="LTR">ALK5</span> في صيغة المستقبل و لها أيضا تأثير مناعي هام . يرتبط الاختراع الحالي بمركبات صيدلانية تتألف من الببتيدات المتعددة بصفتها الأساس النشط، أو بروتينات الربط المفصح عنها و استخداماتها نظرا لتأثيرها على تعديل الجهاز المناعي في أمراض مثل السرطان و الأمراض المصاحبة للتليف و الأمراض المعدية المزمنة.
JOP/2013/0317A 2012-11-09 2013-11-03 البولي بيبتيدات المشتقة من عامل نمو التحويل بيتا واستخداماتها JO3502B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20120158A CU24181B1 (es) 2012-11-09 2012-11-09 POLIPÉPTIDOS DERIVADOS DEL TGFß

Publications (1)

Publication Number Publication Date
JO3502B1 true JO3502B1 (ar) 2020-07-05

Family

ID=49765213

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0317A JO3502B1 (ar) 2012-11-09 2013-11-03 البولي بيبتيدات المشتقة من عامل نمو التحويل بيتا واستخداماتها

Country Status (28)

Country Link
US (1) US9701730B2 (ar)
EP (1) EP2918284B1 (ar)
JP (2) JP6298823B2 (ar)
KR (1) KR102093494B1 (ar)
CN (1) CN104902916B (ar)
AR (1) AR093391A1 (ar)
AU (1) AU2013344022B2 (ar)
BR (1) BR112015010145B1 (ar)
CA (1) CA2887455C (ar)
CL (1) CL2015001252A1 (ar)
CO (1) CO7400865A2 (ar)
CU (1) CU24181B1 (ar)
EA (1) EA031990B1 (ar)
ES (1) ES2857176T3 (ar)
HK (1) HK1213781A1 (ar)
IL (1) IL238621B (ar)
JO (1) JO3502B1 (ar)
MX (1) MX366060B (ar)
MY (1) MY173078A (ar)
NZ (1) NZ707850A (ar)
PE (1) PE20150890A1 (ar)
PH (1) PH12015500807A1 (ar)
SG (1) SG11201502980VA (ar)
TN (1) TN2015000129A1 (ar)
TW (1) TWI615404B (ar)
UA (1) UA115678C2 (ar)
WO (1) WO2014071894A1 (ar)
ZA (1) ZA201504462B (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3041727A1 (en) * 2016-11-18 2018-05-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
PL238850B1 (pl) * 2017-10-19 2021-10-11 Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia Aktywna forma transformującego czynnika wzrostu beta 1 (TGFβ1) do zastosowania w leczeniu pacjentów z glejakami wielopostaciowymi, w przypadku których to glejaków ponad 5% komórek nowotworowych jest EGFRvIII-pozytywna

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1087998A1 (en) * 1998-06-16 2001-04-04 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
WO2000017360A1 (en) * 1998-09-22 2000-03-30 University Of Maryland, Baltimore Cystine knot growth factor mutants
US6677432B1 (en) * 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
WO2006007509A2 (en) * 2004-06-30 2006-01-19 Molecular Logix, Inc. Epidermal growth factor receptor antagonists and methods of use
US7795389B2 (en) * 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
CA2593697A1 (en) * 2005-01-11 2006-07-20 Molecular Logix, Inc. Pan-her antagonists and methods of use
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
BR112012026718A2 (pt) * 2010-04-22 2017-12-19 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct antagonista de leptina sintético, molécula de dna isolada, composição farmacêutica, método para o tratamento de uma doença ou condição, rato transgênico e método de varredura de uma substância tendo atividade terapêutica para uma doença ou distúrbio.

Also Published As

Publication number Publication date
NZ707850A (en) 2019-08-30
TW201431875A (zh) 2014-08-16
ES2857176T3 (es) 2021-09-28
CL2015001252A1 (es) 2015-07-17
IL238621B (en) 2019-12-31
CN104902916B (zh) 2018-04-13
JP6298823B2 (ja) 2018-03-20
BR112015010145B1 (pt) 2022-06-07
CN104902916A (zh) 2015-09-09
AU2013344022B2 (en) 2016-12-15
JP6608473B2 (ja) 2019-11-20
EP2918284B1 (en) 2021-02-17
PE20150890A1 (es) 2015-06-10
JP2018111703A (ja) 2018-07-19
WO2014071894A1 (es) 2014-05-15
KR102093494B1 (ko) 2020-03-26
IL238621A0 (en) 2015-06-30
HK1213781A1 (zh) 2016-07-15
CU24181B1 (es) 2016-04-25
MX2015005875A (es) 2015-09-10
UA115678C2 (uk) 2017-12-11
EP2918284A1 (en) 2015-09-16
ZA201504462B (en) 2018-11-28
US20150284441A1 (en) 2015-10-08
CA2887455A1 (en) 2014-05-15
CU20120158A7 (es) 2014-06-27
SG11201502980VA (en) 2015-06-29
CO7400865A2 (es) 2015-09-30
US9701730B2 (en) 2017-07-11
AU2013344022A1 (en) 2015-05-28
EA031990B1 (ru) 2019-03-29
CA2887455C (en) 2022-05-17
JP2015535000A (ja) 2015-12-07
MY173078A (en) 2019-12-25
BR112015010145A2 (ar) 2017-08-22
MX366060B (es) 2019-06-26
TN2015000129A1 (en) 2016-10-03
KR20150083848A (ko) 2015-07-20
EA201590914A1 (ru) 2015-09-30
AR093391A1 (es) 2015-06-03
PH12015500807A1 (en) 2015-06-08
TWI615404B (zh) 2018-02-21

Similar Documents

Publication Publication Date Title
MY162324A (en) Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
MX2018001567A (es) Novedosos polipeptidos de fusion especificos para lag-3 y pd-1.
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
PH12017500042A1 (en) Interleukin-2/interleukin-2-receptor alpha fusion proteins and methods of use
ECSP14030742A (es) Proteínas del factor 21 de crecimiento del fibroblasto
WO2014176373A3 (en) Interleukin-10 compositions and uses thereof
WO2015061416A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
EA201390681A1 (ru) Производные полипептиды il-2 с агонистической активностью для лечения рака и хронических инфекций
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
MX2016010953A (es) Proteinas de fc multimericas.
MX2018015914A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina.
WO2014136064A3 (en) Immunogenic fusion polypeptides
WO2017096327A3 (en) Compositions and methods for reducing immune responses against chimeric antigen receptors
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
MX350707B (es) Composiciones antigenas y procedimientos.
UA114298C2 (uk) Пептид торк та вакцина, що його містить
JO3502B1 (ar) البولي بيبتيدات المشتقة من عامل نمو التحويل بيتا واستخداماتها
WO2013066731A3 (en) Protective vaccine based on staphylococcus aureus sa2451 protein
TN2014000395A1 (en) Antibodies to bradykinin b1 receptor ligands
MX2014010873A (es) Lotes de adenovirus recombinantes con extremos alterados.
TH167988A (th) พอลิเพพไทด์ที่อนุพัทธ์จาก tgfbeta และการใช้ของมัน
ES2426017A2 (es) Microemulsión que comprende colagenasa y usos